Colorectal cancer
Conditions
Interventions
MPDX constructed from the patients tumor sample:Oxaliplatin, Leucovorin, 5-Fluorouracil
MPDX constructed from the patients tumor sample: Irinotecan + Calcium Leucovorin + 5-Fluorouracil
MPDX constructed from the patients tumor sample:Oxaliplatin, Leucovorin, 5-Fluorouracil, Cetuximab
MPDX constructed from the patients tumor sample:Regorafenib
Sponsors
Tianjin People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18–75 years, regardless of sex. 2. Histopathologically confirmed colorectal cancer requiring systemic anticancer therapy. 3. Availability of fresh tumor tissue obtainable via surgical resection or biopsy. 4. Presence of measurable lesions according to RECIST 1.1 criteria, evaluable by CT or MRI. 5. ECOG performance status 0–2, with an expected survival of >= 3 months. 6. For postoperative patients: prior failure of anticancer therapy (chemotherapy and/or targeted therapy) must be >= 4 weeks before enrollment (date of informed consent), and all related adverse events must have resolved to <= Grade I per NCI-CTCAE v5.0. 7. Patients must voluntarily participate, provide written informed consent, demonstrate good compliance, and be willing to actively undergo treatment and adhere to follow-up schedules.
Exclusion criteria
Exclusion criteria: 1. Currently participating in another drug clinical trial. 2. Patients with hepatic, renal, or bone marrow hematopoietic function not meeting the requirements for chemotherapy. 3. Patients unwilling to receive subsequent chemotherapy with anticancer drugs or regimens recommended by the investigator based on the test results after prior treatment failure. 4. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in diameter of maximum liver metastases (according to RECIST 1.1);Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate;Serum Tumor Marker;Safety Indicators; | — |
Countries
China
Contacts
Public ContactYu Yongjun
Tianjin People's Hospital
Outcome results
None listed